Head-to-head · Cost-Efficiency Index
MDLive vs WePeptideRx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
MDLive
Cost-first shoppers who want not a fit for GLP-1 price shopping -- best suited to patients who already have MDLIVE access for general primary care.
Visit MDLiveWePeptideRx
Cost-first shoppers who want transparent, all-in per-dose GLP-1 pricing with a named medical director and a real 90-day prepay discount.
Visit WePeptideRxThe verdict
MDLive and WePeptideRx tie on the Cost-Efficiency Index at 50/100, so neither wins outright on the numbers. For most shoppers we'd start with MDLive (ranked #410, a hair above #417) — Cost-first shoppers who want not a fit for GLP-1 price shopping -- best suited to patients who already have MDLIVE access for general primary care. But WePeptideRx is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs MDLive.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | MDLive | WePeptideRx |
|---|---|---|
| Cost-Efficiency Index | 50/100 | 50/100 |
| Semaglutide / mo | Not disclosed | $189/mo (0.25 mg dose, bundle, plus a separate fee, compounded) |
| Tirzepatide / mo | Not disclosed | $199/mo (2.5 mg dose, bundle, plus a separate fee, compounded) |
| Semaglutide / yr (modeled) | — | $2,268 |
| Tirzepatide / yr (modeled) | — | $2,388 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #410 | #417 |
MDLive
50/100Where the value is
- Backed by a major, established telehealth/insurance parent (Evernorth/Cigna)
- Access to FDA-approved branded anti-obesity medications, not unregulated compounds
- Broad general primary-care telehealth infrastructure
The tradeoffs
- No dedicated GLP-1 or weight-loss program -- medications are folded into general primary care visits only
- No medication-specific pricing published anywhere
WePeptideRx
50/100Where the value is
- Full dose-by-dose price ladder published with no signup required — 5 tiers for semaglutide, 6 for tirzepatide, each with exact mg dose and matching monthly cost
- Genuinely all-in pricing — consultation, medication, and shipping in one number, no separate visit fee
- Named Medical Director, Hridyesh Nat, MD — a real correction to the current record, which lists this as undisclosed
The tradeoffs
- The lowest advertised monthly rate ($166-176 effective) is NOT the month-to-month price — it requires prepaying a 3-month, $499-529 lump sum
- Pharmacy partner is not named on the pricing page
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.